Noradrenaline in Parkinson's Disease: From Disease Progression to Current Therapeutics

E-ISSN： 1875-533x|14|22|2330-2334

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.14, Iss.22, 2007-09, pp. : 2330-2334

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Levodopa/carbidopa and Parkinson's disease progression

Inpharma, Vol. 1, Iss. 1468, 2004-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease

Current Drug Metabolism, Vol. 16, Iss. 8, 2015-10 ,pp. : 705-712

Bentham Science Publishers

Access to resources Recommend Favorite

Motor complications, levodopa metabolism and progression of Parkinson's disease

By Müüller Thomas

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 7, 2011-07 ,pp. : 847-855

Informa Healthcare

Access to resources Recommend Favorite

Ubidecarenone may slow progression of Parkinson's disease

Inpharma, Vol. 1, Iss. 1361, 2002-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

An Overview on the Role of α -Synuclein in Experimental Models of Parkinson’s Disease from Pathogenesis to Therapeutics

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 15, Iss. 10, 2016-12 ,pp. : 1240-1252

Bentham Science Publishers

Access to resources Recommend Favorite